Capreomycin is an antibiotic, which is used in combination other antituberculosis drugs fro the treatment of pulmonary infections caused by capreomycin-susceptible strains of M. tuberculosis when the primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli. Little is known about capreomycin's exact mechanism of action, but it is thought to inhibit protein synthesis by binding to the 70S ribosomal unit. Capreomycin also binds to components in the bacterial cell which result in the production of abnormal proteins.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2363965 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | CAPASTAT SULFATE Approved UseCapastat Sulfate, which is to be used concomitantly with other appropriate antituberculosis agents, is indicated in pulmonary infections caused by capreomycin-susceptible strains of M. tuberculosis when the primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli. Susceptibility studies should be performed to determine the presence of a capreomycin-susceptible strain of M. tuberculosis. Launch Date1971 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Capreomycin in the treatment of atypical mycobacterial disease in HIV-positive patients. | 2002 Jul |
|
| Capreomycin is active against non-replicating M. tuberculosis. | 2005 Apr 1 |
|
| Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. | 2005 Aug |
|
| Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs. | 2006 Jul 21 |
|
| Capreomycin--a polypeptide antitubercular antibiotic with unusual binding properties toward copper(II). | 2012 Jan |
Sample Use Guides
Intravenously: Capastat Sulfate (Capreomycin for Injection) should be diluted in
100 mL of 0.9% Sodium Chloride Injection and administered over 60 minutes.
Intramuscularly — Reconstituted Capastat Sulfate should be given by deep intramuscular injection into a large muscle mass, since superficial injection may be associated with increased pain and the development of sterile abscesses. For administration of a 1-g dose, the entire contents of the vial should be given. For doses lower than 1 g, the following dilution table may be used.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QJ04AB30
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
||
|
NDF-RT |
N0000175483
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
||
|
NCI_THESAURUS |
C280
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
||
|
LIVERTOX |
NBK548641
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
||
|
NCI_THESAURUS |
C2363
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
||
|
WHO-ATC |
J04AB30
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.4
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m3029
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL2221250
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | |||
|
78903
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB01028MIG
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | |||
|
DB00314
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | |||
|
3211
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | |||
|
CAPREOMYCIN
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | |||
|
3063
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | |||
|
DTXSID8040989
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | |||
|
1145
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | |||
|
C72607
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | |||
|
D002207
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | |||
|
Capreomycin
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | |||
|
11003-38-6
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY | |||
|
232HYX66HC
Created by
admin on Fri Dec 15 15:41:08 GMT 2023 , Edited by admin on Fri Dec 15 15:41:08 GMT 2023
|
PRIMARY |
All of the following components must be present:
ACTIVE MOIETY
